A Korean biotech company has developed a first-in-class Rheumatoid Arthritis (RA) drug acting in the human joints by targeting a recombinant protein. The company has long-standing experts with extensive experience for more than 30 years so that drug development and commercialization can be implemented without difficulty. The team’s core competency is the ability to perform at a high-quality level in specific consulting projects for decades such as IND (Investigational New Drug), clinical trials, marketing approvals in home and abroad, protein/antibody therapeutics, cell/gene therapy, vaccines, etc.
The Problem: The human’s natural protein is involved in an immune antibody that is able to maintain a balance of immune homeostasis under normal physiological conditions. The natural protein has two active domains connected by a peptide linker (a short chain of amino acids). However, due to its low stability and solubility, the linker is easily degraded under normal conditions. This would be difficult for linkers to recover the damaged joint and increase the joint healing.
The Solution: The new recombinant protein is to solve the problem for Rheumatoid Arthritis (RA) treatments. By controlling and balancing the related cells of the RA, the recombinant protein enables joints to maintain the immune system without the linker’s help; also, it helps them have a solid resistance to protease with high stability and solubility. The company has acquired the whole Rheumatoid Arthritis (RA) technology, including the patent ownership of the material from Japan in 2018.
The Korean company is looking for pharmaceutical or biotech partners with extensive experience who are interested in acquiring the new therapeutic technology of RA drug under a license agreement. By licensing out their technology, they want to enhance and boost performance and quality in the bio chemical sector.